Disruption of Brca2-Rad51 Complex in Breast Cancer Cells: Therapeutic Implications

Abstract

BRCA2-Rad5l interaction is required for the Rad5l-related DNA repair pathway. Thus, inhibition of their interaction is expected to sensitize tumor cells to certain DNA damaging agents. A panel of 14080 natural compounds from the Chinese National Center for Drug Screening has been partially screened using a yeast two-hybrid system utilizing specific Rad5l/BRCA2 constructs. Growth of the Rad5l/BRCA2 yeast strain in different media lead us to the selection of 20 candidate inhibitors for BRAC2-Rad5l interaction. Three of these compounds present minimal toxicity to the yeast strains respect to their specific inhibitory activity and thus are the first candidates to be tested for their ability to sensitize breast cancer cells to cisplatin.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Sep 01, 2005
Accession Number
ADA446326

Entities

People

  • Raquel S. Aloyz

Organizations

  • Jewish General Hospital

Tags

DTIC Thesaurus Topics

  • Amino Acids
  • Biomedical Research
  • Breast Cancer
  • Cell Line
  • Cells
  • Gamma Rays
  • Genetic Structures
  • Genetics
  • Health Services
  • Hybrid Systems
  • Inhibition
  • Inhibitors
  • Ionizing Radiation
  • Neoplasms
  • Nitrogen Compounds
  • Toxicity

Fields of Study

  • Biology

Readers

  • Breast cancer cell signaling and growth regulation.
  • Oncology

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech